Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

67%(2 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_1

80%

Ph phase_2

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

Phase 2Efficacy & side effects

1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(2)

Detailed Status

Completed3

Withdrawn1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (80.0%)

Phase 21 (20.0%)

Trials by Status

withdrawn120%

completed360%

terminated120%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_1

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

NCT02661815

withdrawnphase_1

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

NCT02856568

Clinical Trials (5)

Showing 5 of 5 trials

NCT05229042Phase 1

A Study to Investigate the Safety and Efficacy of Ricolinostat

Completed

NCT03176472Phase 2

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

Completed

NCT05193851Phase 1

Evaluate the Safety and Pharmacokinetics of Ricolinostat

Completed

NCT02661815Phase 1

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

Terminated

NCT02856568Phase 1

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5